SCHEDULE 14A INFORMATION

      Proxy Statement Pursuant to Section 14(a) of the Securities Exchange
                         Act of 1934 (Amendment No. ___)

Filed by the Registrant [ ]

Filed by a Party other than the Registrant [X]

Check the appropriate box:

  [ ]   Preliminary Proxy Statement
  [ ]   Confidential, for Use of the Commission Only
         (as permitted by Rule 14a-6(e)(2))
  [ ]   Definitive Proxy Statement
  [X]   Definitive Additional Materials
  [ ]   Soliciting Material Pursuant to ss.240.14a-11(c) or ss.240.14a-12

                                  IMMUCOR, INC.
             (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

                               KAIROS PARTNERS LP
                             KAIROS PARTNERS GP, LLC
                           AIM HIGH ENTERPRISES, INC.
     (NAME OF PERSON(S) FILING PROXY STATEMENT IF OTHER THAN THE REGISTRANT)

Payment of Filing Fee (Check the appropriate box:

  [X]   No Fee Required
  [ ]   Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

        1)    Title of each class of securities to which transaction applies:

        2)    Aggregate number of securities to which transaction applies:

        3)    Per unit price or other underlying value of transaction computed
              pursuant to Exchange Act Rule 0-11 (Set forth the amount on which
              the filing fee is calculated and state how it was determined):

        4)    Proposed maximum aggregate value of transaction:

        5)    Total fee paid:

  [ ]   Fee paid previously with preliminary materials.
  [ ]   Check box if any part of the fee is offset as provided by Exchange Act
        Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
        paid previously. Identify the previous filing by registration statement
        number, or the Form or Schedule and the date of its filing.

        1)    Amount Previously Paid:
                                     -------------------------------------------
        2)    Form, Schedule or Registration Statement No.:
                                                           ---------------------
        3)    Filing Party:
                           -----------------------------------------------------
        4)    Date Filed:
                         -------------------------------------------------------




                      IMMUCOR'S SHAREHOLDERS CAN DO BETTER

DEAR FELLOW IMMUCOR STOCKHOLDER:

       Kairos Partners invests in promising companies within the healthcare
industry. Like many of you, we purchased our shares in IMMUCOR because we
believe that it should be an outstanding company. The transfusion diagnostic
business IS A WELL ESTABLISHED TECHNOLOGY. Health care institutions and
providers UTILIZE THE PRODUCT GLOBALLY. Furthermore, there are FEW COMPETITORS
in the market - - Immucor is a leading player. However, like other Immucor
investors, we have watched the Company's financial performance with INCREASING
CONCERN AND DISAPPOINTMENT. Rather than completely liquidating our investment,
or suffering in silence, WE HAVE DECIDED TO EXERCISE OUR RIGHT AS A SHAREHOLDER.
Kairos has nominated four outstanding and experienced professional individuals
to SERVE AS A MAJORITY on Immucor's board, AS INDEPENDENT OUTSIDE DIRECTORS.
Please vote the enclosed BLUE proxy card today.

                     SO WHAT WENT WRONG WITH IMMUCOR?

       o    The STOCK PRICE HAS DECLINED from a high of $18.875 during the first
            quarter of fiscal 2000, to a low of $2.20 during the fourth quarter
            of fiscal 2001, A DECLINE OF 88%. Even at the more recent price of
            approximately $7.00, the stock has declined 63% SINCE THE FIRST
            QUARTER OF FISCAL 2000.


       o    The acquisitions completed by the Company since October 1998 have
            contributed to the current debt load. The Company's TOTAL DEBT
            INCREASED FROM $8.2 MILLION on August 31, 1998 TO $45.0 MILLION on
            August 31, 2001. During that period, the Company's CASH HAS
            DECREASED FROM $12.7 MILLION TO $4.1 MILLION, respectively.
            Following the Company's recent breach of covenants and renegotiated
            bank agreement, the Company disclosed in its Annual Report filed
            with the SEC that THE BANK HAS A "...SECURITY INTEREST IN
            SUBSTANTIALLY ALL OF THE COMPANY'S ASSETS..." which raises the
            possibility that A REPEAT by the Company of its most recent problems
            with the bank COULD RESULT IN FORECLOSURE, leaving stockholders with
            nothing to show for their investment.




       o    The current BOARD HAS ELIMINATED TWO OUTSIDE DIRECTORS.
            MANAGEMENT NOW CONTROLS 50% OF THE BOARD. We are concerned that,
            in making decisions regarding current management, this reduction
            in outside directors increases the possibility that the Board MAY
            BE PREVENTED from MAKING CHANGES TO CURRENT MANAGEMENT or taking
            other actions that they believe would benefit all shareholders.



IS THIS THE TYPE OF PERFORMANCE WHICH IMMUCOR'S SHAREHOLDERS SEEK?"





THIS YEAR'S ANNUAL MEETING OF SHAREHOLDERS PROVIDES YOU WITH A UNIQUE
OPPORTUNITY TO ELECT A NEW BOARD OF DIRECTORS AND TO CHANGE THE FUTURE COURSE OF
THE COMPANY.
                   IMMUCOR'S SHAREHOLDERS SHOULD EXPECT BETTER

                               THE KAIROS PLATFORM

       If the Kairos nominees are elected to serve on the Board of Directors,
Kairos believes that the Board will be better positioned to develop and
implement the action plans necessary to improve the Company's performance and
increase the Company's value for all shareholders. If elected, these nominees
could work to focus the Company and Board on certain areas in which we believe
the Company now falls short.


       o    The Company operates in a mature, but necessary, market. It has
            limited competition and claims in its SEC filings to be the market
            leader. Kairos believes that a STRONG, INDEPENDENT BOARD will chart
            a path that will reflect that mature, but necessary market, to focus
            on optimizing the utilization of automated equipment and to RESTORE
            THE CONFIDENCE OF IMMUCOR'S CUSTOMERS in the Company's products and
            future.



       o    Immucor's debt level must be managed for the LONG TERM. The
            consequences of its recent breaches of debt covenants were THE
            PAYMENT OF A RESTRUCTURING FEE TO THE COMPANY'S LENDER OF $750,000
            and INCREASED INTEREST COSTS. The Company also agreed to RAISE $5.0
            MILLION IN JUNIOR CAPITAL by December 31, 2001, which may result in
            SIGNIFICANT DILUTION to all shareholders. In addition, as disclosed
            by the Company in its annual report for this year, "IF THE JUNIOR
            CAPITAL IS NOT RECEIVED BY APRIL 30, 2002, ALL EXISTING CREDIT
            FACILITIES WOULD BE RESET TO MATURE ON FEBRUARY 28, 2003." As
            discussed above, with all of the Company's assets now being subject
            to a lien to the lender, any future problems with the lender could
            be disastrous for all shareholders.


       o    COMMUNICATIONS WITH SHAREHOLDERS MUST BE IMPROVED. Kairos believes
            the markets do not understand the significance of the Company's
            market position and prospects for growth which has contributed to
            the declining stock price. We believe this results, in part, from
            the Company not providing the opportunity for management to
            communicate directly with shareholders through periodic conference
            calls. If the Kairos nominees are elected, Kairos believes that the
            new Board will MAKE INVESTOR RELATIONS AND CONCERNS A PRIORITY.




                      IMMUCOR'S SHAREHOLDERS DESERVE BETTER

                               THE KAIROS NOMINEES


       JOHN F. MCGUIRE, III served as Vice President and General Manager of the
Ortho Diagnostics Business Unit of Johnson & Johnson, Inc., the Company's only
competitor in the U.S. The Board of Directors of HemaSure, Inc, a blood
filtration technology company, subsequently recruited Mr. McGuire as CEO. He
successfully resolved various FDA regulatory issues, successfully defended
Hemasure in a series of patent infringement litigations brought by a large
public blood flitration company and oversaw the turnaround of this troubled
company. He is a member of the Board of Trustees of the National Blood
Foundation Trust Fund.


       RONALD O. GILCHER, M.D., F.A.C.P., is Board Certified in Internal
Medicine and Hematology and is a Fellow of the American College of Physicians.
Dr. Gilcher serves on the U.S. Department of Health and Human Services Advisory
Committee on Blood Safety and Availability. Dr. Gilcher has been the Chief
Operating Officer and Medical Director of the Sylvan N. Goldman Center, Oklahoma
Blood Institute since 1979.

       PIERRE G. CASSIGNEUL is currently serving as Vice President, Blood
Glucose Monitoring, Becton Dickinson Consumer Healthcare. He was employed by the
Ortho Diagnostics Business Unit of Johnson & Johnson, Inc., as Vice President
and General Manager of the AIDS and Hepatitis Business Unit. He has twenty years
of operational experience in the diagnostics industry.

       PETER R. WHITE served as a Managing Director for Fleet Securities, Inc.,
in units that financed the acquisition of businesses by private equity firms. He
was directly involved in analyzing, conducting comprehensive due diligence,
underwriting and distributing over $1 billion in new debt financings.

       Kairos believes that Jack McGuire, Dr. Ron Gilcher and Pierre Cassigneul
have significant, direct experience within the transfusion medicine industry,
and that Peter White has significant, direct experience with long-term financial
planning. Kairos believes they have successfully dealt with issues similar to
those facing Immucor today.


       DO YOU BELIEVE MANAGEMENT WHEN THEY SAY THAT THE COMPANY TURNAROUND
HAS BEEN ACHIEVED?





       In the coming weeks you may receive letters and phone calls telling you
the proxy fight is hostile and expensive. All Immucor shareholders have the
right to nominate members of the Board of Directors.


    Ask yourself -- "IS IT HOSTILE TO EXERCISE YOUR RIGHTS AS A SHAREHOLDER?"

                        Please vote the BLUE card today.